Advancing Cancer Research Through Proteogenomics and Greater Collaboration

Advancing Cancer Research Through Proteogenomics and Greater Collaboration
Glioblastoma study could lead to new treatments, including better immunotherapies
Prostate cancer screening is typically done by evaluation of levels of prostate-specific antigens (PSA). Unfortunately, its effectiveness in stratifying low risk patients from those with aggressive (AG)...
Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer. A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. The...
Activating point mutations in ErbB/Her2 receptor tyrosine kinases have an infamous role in promoting oncogenesis across several different cancers, including breast and lung. Heterodimer activation of the ErbB2/ErbB3 oncogenic unit induces cancer cell proliferation via PI3K/AKT signaling...
In case you missed it, this final article (part 2 of 2) in the Investigator Spotlight Series, developed and written by Dr.
Data reported can guide new therapeutic avenues for pediatric patients
A comprehensive “proteogenomic” analysis of the proteins, genes, and RNA transcription involved in pediatric brain tumors has yielded a more complete understanding of these tumors, which are the leading cause of cancer...
In case you missed it, this third article (part 1 of 2) in the Investigator Spotlight Series, developed and written by Dr.
Announcing our newest data release for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Lung Squamous Cell Carcinoma (LSCC) Discovery study! Because...
In a recent publication in the journal Clinical Chemistry, CPTAC investigators from Fred Hutchinson Cancer Research Center described a...